1Smelt VA, Mardon HJ, Sim E. Placental expression of arylamine N-acetyltransferases: evidence for linkage disequilibrium between NAT1.10 and NAT2.4 alleles of the two human arylamine N-transferase loci NAT1 and NAT2. Pharmacol Toxicol,1998, 83:149～157.
2Grant DM, Hughes NC, Janezic SA, Goodfellow GH, Chen HJ, Gaedigk A, Yu VL, Grewal R. Human acetyltransferase polymorphisms. Mutat Res. 1997,376: 61～70.
3Nakamura H, Uetrecht J, Cribb AE, Miller MA, Zahid N, Hill J, Josephy PD, Grant DM, Spielberg SP.In vitro formation, disposition and toxicity of N-acetoxy-sulfamethoxazole, a potential mediator of sulfamethoxazole toxicity. J Pharmacol Exp Ther. 1995,274: 1099～1104.
4Gonzalez FJ, Skoda RC, Kimura S, Umeno M, Zanger UM, Nebert DW, Gelboin HV, Hardwick JP, Meyer UA. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature. 1988,331: 442～446.
5Nebert DW. Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist? Am J Hum Genet. 1997,60: 265～271.
6Evans WE, Johnson JA. Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu Rev Genomics Hum Genet. 2001,2: 9～39.
8Sauer S, Lechner D, Berlin K, Plancon C, Heuermann A, Lehrach H, Gut IG. Full flexibility genotyping of single nucleotide polymorphisms by the GOOD assay. Nucleic Acids Res. 2000,28: E100.
9Weinstein JN. Pharmacogenomics--teaching old drugs new tricks. New Engl J Med. 2000,343: 1408～1409.
10Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. New Engl J Med. 1998,338: 499～505.
4Leschziner G D, Andrew T, Pirmohamed M, et al. AB- CB 1 genotype and PGP expression, function and therapeu- tic drugresponse: a critical review and recommendations for future research [J]. Pharmacogenomics J, 2007, 7 (3): 154-179.
